Gentamicin and norfloxacin prophylaxis for transrectal ultrasound-guided prostate biopsy
Cameron J. Jeremiah A B E , Denis W. Spelman A , Peter L. Royce C and Allen C. Cheng A D
+ Author Affiliations
- Author Affiliations
A Infectious Diseases and Microbiology Unit, Alfred Hospital, 55 Commercial Road, Melbourne, Vic. 3004, Australia.
B Infectious Diseases Unit, St Vincent’s Hospital, 41 Victoria Parade, Fitzroy, Vic. 3064, Australia.
C Department of Urology, Alfred Hospital, 55 Commercial Road, Melbourne, Vic. 3004, Australia.
D Department of Epidemiology and Preventive Medicine, Monash University, 99 Commercial Road, Melbourne, Vic. 3004, Australia.
E Corresponding author. Email: cameron.jeremiah@svhm.org.au or cameronjeremiah@hotmail.com
Healthcare Infection 18(2) 67-71 https://doi.org/10.1071/HI12043
Submitted: 5 October 2012 Accepted: 21 November 2012 Published: 10 April 2013
Abstract
Background: Transrectal ultrasound guided prostate biopsy (TRUSPB) is the mainstay of diagnosis for prostate cancer. Clinical trials have established that antibiotic prophylaxis is effective in reducing infective complications, but breakthrough bacteraemia has been described with multiresistant organisms. We reviewed the rate of bacteraemia and re-admission in patients undergoing TRUSPB.
Methods: The Alfred Hospital is a tertiary referral hospital in Melbourne, Australia. The routine antibiotic prophylactic regimen is gentamicin and norfloxacin. Patients undergoing TRUSPB at the Alfred Hospital were linked to databases of blood and urine cultures, and to admissions with infective complications within 14 days.
Results: Between June 2007 and July 2010, 459 patients underwent TRUSPB at the Alfred Hospital. No patient (95% CI: 0, 0.8%) had a positive blood culture, and one patient had a positive urine culture (95% CI: 0.04, 1.2%) within 14 days of the procedure. There were two readmissions: a 66 year old man with systemic culture-negative sepsis, and a 54 year old man with a urinary tract infection. In 50 randomly selected patients, all patients received norfloxacin but only 80% of patients received gentamicin. Between 2007 and 2010, 6.0% of isolates were non-susceptible to norfloxacin, 5.8% were non-susceptible to gentamicin and 3.2% were non-susceptible to both gentamicin and norfloxacin.
Conclusions: Recent reports of breakthrough bacteraemia suggest that effectiveness of single agent fluoroquinolone or gentamicin prophylaxis may be compromised by increasing rates of resistance. Combination prophylaxis with gentamicin and norfloxacin is associated with a low rate of infective complications.
References
[1] Eichler K, Hempel S, Wilby J, Myers L, Bachmann LM, Kleijnen J. Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: a systematic review. J Urol 2006; 175 1605–12.| Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: a systematic review.Crossref | GoogleScholarGoogle Scholar | 16600713PubMed |
[2] Lindert KA, Kabalin JN, Terris MK. Bacteremia and bacteriuria after transrectal ultrasound guided prostate biopsy. J Urol 2000; 164 76–80.
| Bacteremia and bacteriuria after transrectal ultrasound guided prostate biopsy.Crossref | GoogleScholarGoogle Scholar | 10840428PubMed |
[3] Simsir A, Kismali E, Mammadov R, Gunaydin G, Cal C. Is it possible to predict sepsis, the most serious complication in prostate biopsy? Urol Int 2010; 84 395–9.
| Is it possible to predict sepsis, the most serious complication in prostate biopsy?Crossref | GoogleScholarGoogle Scholar | 20224265PubMed |
[4] Carey JM, Korman HJ. Transrectal ultrasound guided biopsy of the prostate. Do enemas decrease clinically significant complications? J Urol 2001; 166 82–5.
| Transrectal ultrasound guided biopsy of the prostate. Do enemas decrease clinically significant complications?Crossref | GoogleScholarGoogle Scholar | 11435829PubMed |
[5] Aron M, Rajeev TP, Gupta NP. Antibiotic prophylaxis for transrectal needle biopsy of the prostate: a randomized controlled study. BJU Int 2000; 85 682–5.
| Antibiotic prophylaxis for transrectal needle biopsy of the prostate: a randomized controlled study.Crossref | GoogleScholarGoogle Scholar | 10759665PubMed |
[6] Crawford ED, Haynes AL, Story MW, Borden TA. Prevention of urinary tract infection and sepsis following transrectal prostatic biopsy. J Urol 1982; 127 449–51.
| 6895918PubMed |
[7] Kapoor DA, Klimberg IW, Malek GH, Wegenke JD, Cox CE, Patterson AL, et al Single-dose oral ciprofloxacin versus placebo for prophylaxis during transrectal prostate biopsy. Urology 1998; 52 552–8.
| Single-dose oral ciprofloxacin versus placebo for prophylaxis during transrectal prostate biopsy.Crossref | GoogleScholarGoogle Scholar | 9763070PubMed |
[8] Roach MB, Figueroa TE, McBride D, George WJ, Neal DE. Ciprofloxacin versus gentamicin in prophylaxis against bacteremia in transrectal prostate needle biopsy. Urology 1991; 38 84–7.
| Ciprofloxacin versus gentamicin in prophylaxis against bacteremia in transrectal prostate needle biopsy.Crossref | GoogleScholarGoogle Scholar | 1866869PubMed |
[9] Shandera KC, Thibault GP, Deshon GE. Variability in patient preparation for prostate biopsy among American urologists. Urology 1998; 52 644–6.
| Variability in patient preparation for prostate biopsy among American urologists.Crossref | GoogleScholarGoogle Scholar | 9763086PubMed |
[10] Young JL, Liss MA, Szabo RJ. Sepsis due to fluoroquinolone-resistant Escherichia coli after transrectal ultrasound-guided prostate needle biopsy. Urology 2009; 74 332–8.
| Sepsis due to fluoroquinolone-resistant Escherichia coli after transrectal ultrasound-guided prostate needle biopsy.Crossref | GoogleScholarGoogle Scholar | 19464041PubMed |
[11] Schaeffer AJ, Montorsi F, Scattoni V, Perroncel R, Song J, Haverstock DC, et al Comparison of a 3-day with a 1-day regimen of an extended-release formulation of ciprofloxacin as antimicrobial prophylaxis for patients undergoing transrectal needle biopsy of the prostate. BJU Int 2007; 100 51–7.
| Comparison of a 3-day with a 1-day regimen of an extended-release formulation of ciprofloxacin as antimicrobial prophylaxis for patients undergoing transrectal needle biopsy of the prostate.Crossref | GoogleScholarGoogle Scholar | 17552953PubMed |
[12] Cormio L, Berardi B, Callea A, Fiorentino N, Sblendorio D, Zizzi V, et al Antimicrobial prophylaxis for transrectal prostatic biopsy: a prospective study of ciprofloxacin vs piperacillin/tazobactam. BJU Int 2002; 90 700–2.
| Antimicrobial prophylaxis for transrectal prostatic biopsy: a prospective study of ciprofloxacin vs piperacillin/tazobactam.Crossref | GoogleScholarGoogle Scholar | 12410751PubMed |
[13] Bouza E, Loeches B, Munoz P. Fever of unknown origin in solid organ transplant recipients. Infect Dis Clin North Am 2007; 21 1033–54. [ix–x.]
| Fever of unknown origin in solid organ transplant recipients.Crossref | GoogleScholarGoogle Scholar | 18061088PubMed |
[14] Cannon GM, Smaldone MC, Paterson DL. Extended-spectrum beta-lactamase gram-negative sepsis following prostate biopsy: implications for use of fluoroquinolone prophylaxis. Can J Urol 2007; 14 3653–5.
| 17784990PubMed |
[15] Feliciano J, Teper E, Ferrandino M, Macchia RJ, Blank W, Grunberger I, et al The incidence of fluoroquinolone resistant infections after prostate biopsy–are fluoroquinolones still effective prophylaxis? J Urol 2008; 179 952–5, discussion 5.
| The incidence of fluoroquinolone resistant infections after prostate biopsy–are fluoroquinolones still effective prophylaxis?Crossref | GoogleScholarGoogle Scholar | 18207185PubMed |
[16] Antoniadou A, Giamarellou H. Fever of unknown origin in febrile leukopenia. Infect Dis Clin North Am 2007; 21 1055–90.
| Fever of unknown origin in febrile leukopenia.Crossref | GoogleScholarGoogle Scholar | 18061089PubMed |
[17] Kamdar C, Mooppan UM, Gulmi FA, Kim H. Multi-drug-resistant bacteremia after transrectal ultrasound guided prostate biopsies in hospital employees and their relatives. Urology 2008; 72 34–6.
| Multi-drug-resistant bacteremia after transrectal ultrasound guided prostate biopsies in hospital employees and their relatives.Crossref | GoogleScholarGoogle Scholar | 18372012PubMed |
[18] Lange D, Zappavigna C, Hamidizadeh R, Goldenberg SL, Paterson RF, Chew BH. Bacterial sepsis after prostate biopsy–a new perspective. Urology 2009; 74 1200–5.
| Bacterial sepsis after prostate biopsy–a new perspective.Crossref | GoogleScholarGoogle Scholar | 19815258PubMed |
[19] Nam RK, Saskin R, Lee Y, Liu Y, Law C, Klotz LH, et al Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol 2010; 183 963–9.
| Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy.Crossref | GoogleScholarGoogle Scholar | 20089283PubMed |
[20] Ng CF, Chan SY. Re: The incidence of fluoroquinolone resistant infections after prostate biopsy–are fluoroquinolones still effective prophylaxis? J. Feliciano, E. Teper, M. Ferrandino, R. J. Macchia, W. Blank, I. Grunberger and I. Colon J Urol 2008; 179: 952–955. J Urol 2008; 180 1570–1, author reply 1.
| Re: The incidence of fluoroquinolone resistant infections after prostate biopsy–are fluoroquinolones still effective prophylaxis? J. Feliciano, E. Teper, M. Ferrandino, R. J. Macchia, W. Blank, I. Grunberger and I. Colon J Urol 2008; 179: 952–955.Crossref | GoogleScholarGoogle Scholar | 18718610PubMed |
[21] Hawkey PM. Prevalence and clonality of extended-spectrum beta-lactamases in Asia. Clin Microbiol Infect 2008; 14 159–65.
| Prevalence and clonality of extended-spectrum beta-lactamases in Asia.Crossref | GoogleScholarGoogle Scholar | 18154540PubMed |
[22] Hawkey PM, Jones AM. The changing epidemiology of resistance. J Antimicrob Chemother 2009; 64 i3–10.
| The changing epidemiology of resistance.Crossref | GoogleScholarGoogle Scholar | 19675017PubMed |
[23] Hirakata Y, Matsuda J, Miyazaki Y, Kamihira S, Kawakami S, Miyazawa Y, et al Regional variation in the prevalence of extended-spectrum beta-lactamase-producing clinical isolates in the Asia-Pacific region (SENTRY 1998–2002). Diagn Microbiol Infect Dis 2005; 52 323–9.
| Regional variation in the prevalence of extended-spectrum beta-lactamase-producing clinical isolates in the Asia-Pacific region (SENTRY 1998–2002).Crossref | GoogleScholarGoogle Scholar | 16165001PubMed |
[24] Hsueh PR, Badal RE, Hawser SP, Hoban DJ, Bouchillon SK, Ni Y, et al Epidemiology and antimicrobial susceptibility profiles of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region: 2008 results from SMART (Study for Monitoring Antimicrobial Resistance Trends). Int J Antimicrob Agents 2010; 36 408–14.
| Epidemiology and antimicrobial susceptibility profiles of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region: 2008 results from SMART (Study for Monitoring Antimicrobial Resistance Trends).Crossref | GoogleScholarGoogle Scholar | 20728316PubMed |
[25] Rahal JJ. Antimicrobial resistance among and therapeutic options against gram-negative pathogens. Clin Infect Dis 2009; 49 S4–10.
| Antimicrobial resistance among and therapeutic options against gram-negative pathogens.Crossref | GoogleScholarGoogle Scholar | 19619021PubMed |
[26] Davidson AJ, Webb DR, Lawrentschuk N, Jennens ID, Sutherland M. Multi-resistant Escherichia coli sepsis following transrectal ultrasound-guided prostate biopsy. Br J Hosp Med (Lond) 2006; 67 98–9.
[27] Otrock ZK, Oghlakian GO, Salamoun MM, Haddad M, Bizri AR. Incidence of urinary tract infection following transrectal ultrasound guided prostate biopsy at a tertiary-care medical center in Lebanon. Infect Control Hosp Epidemiol 2004; 25 873–7.
| Incidence of urinary tract infection following transrectal ultrasound guided prostate biopsy at a tertiary-care medical center in Lebanon.Crossref | GoogleScholarGoogle Scholar | 15518032PubMed |
[28] Adibi M, Hornberger B, Bhat D, Raj G, Roehrborn CG, Lotan Y. Reduction in hospital admission rates due to post-prostate biopsy infections after augmenting standard antibiotic prophylaxis. J Urol 2013; 189 535–40.
| Reduction in hospital admission rates due to post-prostate biopsy infections after augmenting standard antibiotic prophylaxis.Crossref | GoogleScholarGoogle Scholar | 22982426PubMed |
[29] Kennedy K, Collignon P. Colonisation with Escherichia coli resistant to “critically important” antibiotics: a high risk for international travellers. Eur J Clin Microbiol Infect Dis 2010; 29 1501–6.
| Colonisation with Escherichia coli resistant to “critically important” antibiotics: a high risk for international travellers.Crossref | GoogleScholarGoogle Scholar | 20835879PubMed |
[30] Miura T, Tanaka K, Shigemura K, Nakano Y, Takenaka A, Fujisawa M. Levofloxacin resistant Escherichia coli sepsis following an ultrasound-guided transrectal prostate biopsy: report of four cases and review of the literature. Int J Urol 2008; 15 457–9.
| Levofloxacin resistant Escherichia coli sepsis following an ultrasound-guided transrectal prostate biopsy: report of four cases and review of the literature.Crossref | GoogleScholarGoogle Scholar | 18452466PubMed |
[31] Pearson J, Turnidge J, Franklin C, Bell J. Prevalence of antimicrobial resistances in common pathogenic Enterobacteriaceae in Australia, 2004: report from the Australian Group on Antimicrobial Resistance. Commun Dis Intell 2007; 31 106–12.
[32] Ben-Ami R, Rodriguez-Bano J, Arslan H, Pitout JD, Quentin C, Calbo ES, et al A multinational survey of risk factors for infection with extended-spectrum beta-lactamase-producing enterobacteriaceae in nonhospitalized patients. Clin Infect Dis 2009; 49 682–90.
| A multinational survey of risk factors for infection with extended-spectrum beta-lactamase-producing enterobacteriaceae in nonhospitalized patients.Crossref | GoogleScholarGoogle Scholar | 19622043PubMed |